Your browser doesn't support javascript.
The impact of COVID-19 non-pharmaceutical interventions on HIV care continuum in China: An interrupted time series analysis.
Wu, Xinsheng; Wu, Guohui; Ma, Yanmin; Huang, Xiaojie; Yang, Yuecheng; Cai, Yanshan; Luo, Ganfeng; Ma, Ping; Qiao, Ying; Chen, Yuanyi; Lin, Yi-Fan; Gao, Yanxiao; Zhan, Yuewei; Song, Wei; Wang, Yingying; Wang, Rugang; Yang, Xuejuan; Sun, Lijun; Wei, Hongxia; Li, Quanmin; Xin, Xiaoli; Wang, Lijing; Wang, Xicheng; Xie, Ronghui; Yang, Lijuan; Meng, Xiaojun; Zhao, Jin; Li, Linghua; Zhang, Tong; Xu, Junjie; Fu, Gengfeng; Zou, Huachun.
  • Wu X; School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, People's Republic of China.
  • Wu G; Institute for AIDS/STD Control and Prevention, Chongqing Center for Disease Control and Prevention, Chongqing, People's Republic of China.
  • Ma Y; Institute for AIDS/STD Control and Prevention, Henan Provincial Center for Disease, Zhengzhou, People's Republic of China.
  • Huang X; Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, People's Republic of China.
  • Yang Y; Dehong Prefecture Center for Disease Control and Prevention, Dehong, People's Republic of China.
  • Cai Y; Department of AIDS Control and Prevention, Guangzhou Center for Disease Control and Prevention, Guangzhou, People's Republic of China.
  • Luo G; School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, People's Republic of China.
  • Ma P; Department of Infectious Diseases, Tianjin Second People's Hospital, Tianjin, People's Republic of China.
  • Qiao Y; Tianjin Association of STD/AIDS Prevention and Control, Tianjin, People's Republic of China.
  • Chen Y; No.2 Hospital of Huhhot, Huhhot, People's Republic of China.
  • Lin YF; School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, People's Republic of China.
  • Gao Y; School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, People's Republic of China.
  • Zhan Y; School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, People's Republic of China.
  • Song W; Talents and Discipline Office, Shenzhen People's Hospital, Shenzhen, People's Republic of China.
  • Wang Y; Shenyang Center for Disease Control and Prevention, Shenyang, People's Republic of China.
  • Wang R; Department of STD/AIDS Control and Prevention, Shijiazhuang Center for Disease Control and Prevention, Shijiazhuang, People's Republic of China.
  • Yang X; Dalian Public Health Clinical Center, Dalian, People's Republic of China.
  • Sun L; Department of Infectious Diseases, Yunnan Provincial Infectious Disease Hospital/Yunnan AIDS Care Center, Kunming, People's Republic of China.
  • Wei H; Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, People's Republic of China.
  • Li Q; Department of infectious disease, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, People's Republic of China.
  • Xin X; Infectious disease Center, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, People's Republic of China.
  • Wang L; No.6 People's Hospital of Shenyang, Shenyang, People's Republic of China.
  • Wang X; Shijiazhuang Fifth Hospital, Shijiazhuang, People's Republic of China.
  • Xie R; Department of Infectious Diseases, Yunnan Provincial Infectious Disease Hospital/Yunnan AIDS Care Center, Kunming, People's Republic of China.
  • Yang L; Department of Infectious Diseases, Yunnan Provincial Infectious Disease Hospital/Yunnan AIDS Care Center, Kunming, People's Republic of China.
  • Meng X; Department of Infectious Diseases, Yunnan Provincial Infectious Disease Hospital/Yunnan AIDS Care Center, Kunming, People's Republic of China.
  • Zhao J; Emergency Management Office, Wuxi Municipal Center for Disease Control and Prevention, Wuxi, People's Republic of China.
  • Li L; Shenzhen Center for Disease Control and Prevention, Shenzhen, People's Republic of China.
  • Zhang T; Infectious disease Center, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, People's Republic of China.
  • Xu J; Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, People's Republic of China.
  • Fu G; Clinical Research Academy, Peking University Shenzhen Hospital, Peking University, Shenzhen, People's Republic of China.
  • Zou H; Department of STD/AIDS Control and Prevention, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, People's Republic of China.
Lancet Reg Health West Pac ; 29: 100569, 2022 Dec.
Article in English | MEDLINE | ID: covidwho-2246421
ABSTRACT

Background:

China implemented strict non-pharmaceutical interventions to contain COVID-19 at the early stage. We aimed to evaluate the impact of COVID-19 on HIV care continuum in China.

Methods:

Aggregated data on HIV care continuum between 1 January 2017 and 31 December 2020 were collected from centers for disease control and prevention at different levels and major infectious disease hospitals in various regions in China. We used interrupted time series analysis to characterize temporal trend in weekly numbers of HIV post-exposure prophylaxis (PEP) prescriptions, HIV tests, HIV diagnoses, median time intervals between HIV diagnosis and antiretroviral therapy (ART) initiation (time intervals, days), ART initiations, mean CD4+ T cell counts at ART initiation (CD4 counts, cells/µL), ART collections, and missed visits for ART collection, before and after the implementation of massive NPIs (23 January to 7 April 2020). We used Poisson segmented regression models to estimate the immediate and long-term impact of NPIs on these outcomes.

Findings:

A total of 16,780 PEP prescriptions, 1,101,686 HIV tests, 69,659 HIV diagnoses, 63,409 time intervals and ART initiations, 61,518 CD4 counts, 1,528,802 ART collections, and 6656 missed visits were recorded during the study period. The majority of outcomes occurred in males (55·3-87·4%), 21-50 year olds (51·7-90·5%), Southwestern China (38·2-82·0%) and heterosexual transmission (47·9-66·1%). NPIs was associated with 71·5% decrease in PEP prescriptions (IRR 0·285; 95% CI 0·192-0·423), 36·1% decrease in HIV tests (0·639, 0·497-0·822), 32·0% decrease in HIV diagnoses (0·680, 0·511-0·904), 59·3% increase in time intervals (1·593, 1·270-1·997) and 17·4% decrease in CD4 counts (0·826, 0·746-0·915) in the first week during NPIs. There was no marked change in the number of ART initiations, ART collections and missed visits during the NPIs. By the end of 2020, the number of HIV tests, HIV diagnoses, time intervals, ART initiations, and CD4 counts reached expected levels, but the number of PEP prescriptions (0·523, 0·394-0·696), ART collections (0·720, 0·595-0·872), and missed visits (0·137, 0·086-0·220) were still below expected levels. With the ease of restrictions, PEP prescriptions (slope change 1·024/week, 1·012-1·037), HIV tests (1·016/week, 1·008-1·026), and CD4 counts (1·005/week, 1·001-1·009) showed a significant increasing trend.

Interpretation:

HIV care continuum in China was affected by the COVID-19 NPIs at various levels. Preparedness and efforts to maintain the HIV care continuum during public health emergencies should leverage collaborations between stakeholders.

Funding:

Natural Science Foundation of China.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies Language: English Journal: Lancet Reg Health West Pac Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies Language: English Journal: Lancet Reg Health West Pac Year: 2022 Document Type: Article